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A B S T R A C T
Background
Wilson's disease, first described by Samuel Wilson in 1912, is an autosomal recessive metabolic disorder resulting from mutations in the
ATP7B gene. The disease develops as a consequence of copper accumulating in affected tissues.
There is no gold standard for the diagnosis of Wilson's disease, which is often delayed due to the non-specific clinical features and the
need for a combination of clinical and laboratory tests for diagnosis. This delay may in turn affect clinical outcome and has implications
for other family members in terms of diagnosis. The Leipzig criteria were established to help standardise diagnosis and management.
However, it should be emphasised that these criteria date from 2003, and many of these have not been formally evaluated; this review
examines the evidence behind biochemical testing for Wilson's disease.
Objectives
To determine the diagnostic accuracy of three biochemical tests at specified cut-oJ levels for Wilson's disease. The index tests covered
by this Cochrane Review are caeruloplasmin, 24-hour urinary copper and hepatic copper content. These tests were evaluated in those
with suspected Wilson's disease and appropriate controls (either healthy or those with chronic liver disease other than Wilson's). In the
absence of a gold standard for diagnosing Wilson's disease, we have used the Leipzig criteria as a clinical reference standard.
To investigate whether index tests should be performed in all individuals who have been recommended for testing for Wilson's disease,
or whether these tests should be limited to subgroups of individuals.
Search methods
We identified studies by extensive searching of, e.g. the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, the
Web of Science and clinical trial registries (29 May 2019).
Date of the most recent search of the Cochrane Cystic Fibrosis and Genetic Disorders Inborn Errors of Metabolism Register: 29 May 2019.
Selection criteria
We included prospective and retrospective cohort studies that assessed the diagnostic accuracy of an index test using the Leipzig criteria
as a clinical reference standard for the diagnosis of Wilson's disease.
Data collection and analysis
Two review authors independently reviewed and extracted data and assessed the methodological quality of each included study using the
QUADAS-2 tool. We had planned to undertake meta-analyses of the sensitivity, specificity at relevant cut-oJs for each of the biochemical
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tests for Wilson's, however, due to differences in the methods used for each biochemical index test, it was not possible to combine the
results in meta-analyses and hence these are described narratively.
Main results
Eight studies, involving 5699 participants (which included 1009 diagnosed with Wilson's disease) were eligible for inclusion in the review.
Three studies involved children only, one adults only and the four remaining studies involved both children and adults. Two evaluated
participants with hepatic signs and six with a combination of hepatic and neurological signs and symptoms of Wilson's disease, as well as
pre-symptomatic individuals. The studies were of variable methodological quality; with high risk if bias for participant selection and the
reference standard used being of greatest methodological concern. Key differences between studies include differences in assay method-
ology, different cut-oJ values for diagnostic thresholds, different age and ethnicity groups. Concerns around study design imply that di-
agnostic accuracy figures may not transfer to populations outside of the relevant study.
Index test: caeruloplasmin
Five studies evaluated various thresholds of caeruloplasmin (4281 participants, of which 541 had WD). For caeruloplasmin a cut-oJ of 0.2
g/L as in the Leipzig criteria achieved a sensitivity of 77.1% to 99%, with variable specificity of 55.9% to 82.8%. Using the cut-oJ of 0.1 g/L
of the Leipzig criteria seemed to lower the sensitivity overall, 65% to 78.9%, while increasing the specificity to 96.6% to 100%.
Index test: hepatic copper
Four studies evaluated various thresholds of hepatic copper (1150 participants, of which 367 had WD). The hepatic copper cut-oJ of 4
μmol/g used in the Leipzig criteria achieved a sensitivity of 65.7% to 94.4%, with a variable specificity of 52.2% to 98.6%.
Index test: 24-hour urinary copper
Three studies evaluated various thresholds of 24-hour urinary copper (268 participants, of which 101 had WD). For 24-hour urinary copper,
a cut-oJ of 0.64 to 1.6 μmol/24 hours used in the Leipzig criteria achieved a variable sensitivity of 50.0% to 80.0%, with a specificity of
75.6% to 98.3%.
Authors' conclusions
The cut-oJs used for caeruloplasmin, 24-hour urinary copper and hepatic copper for diagnosing Wilson's disease are method-dependent
and require validation in the population in which such index tests are going to be used. Binary cut-oJs and use of single-test strategies to
rule Wilson's disease in or out is not supported by the evidence in this review. There is insufficient evidence to inform testing in specific
subgroups, defined by age, ethnicity or clinical subgroups.
P L A I N   L A N G U A G E   S U M M A R Y
Laboratory blood, urine tests and liver biopsy used for the diagnosis of Wilson's disease in children and adults
Why is improving Wilson's disease diagnosis important?
Wilson's disease is an inherited disease that leads to a build-up of copper in affected parts of the body. Diagnosis usually occurs in children
or young adults, but has been seen in adults over 60 years of age. Copper build-up begins in the liver progressing over time to affect the
brain; however, the challenge for doctors is that liver disease in Wilson's disease has non-specific features and standard liver blood tests
may be normal, even with advanced scarring of the liver or cirrhosis. Early diagnosis allows earlier treatment, however, other causes of
chronic liver disease may cause false-positive results and, depending on cut-oJ values used for testing, may result in further unnecessary
testing. Conversely, false-negative results may also arise when a single-test strategy for diagnosis is used, possibly leading to a delay in
treatment.
What is the aim and what was included in this review?
We aimed to examine the accuracy of three commonly used diagnostic tests to correctly identify Wilson's disease. These tests are: caeru-
loplasmin (a protein that carries copper in blood); copper in the urine; and copper in the liver. Initial evaluation usually involves checking
an individual's eyes for signs of Wilson's disease and a blood test for caeruloplasmin, as this is the most widely accessible biochemical
test for Wilson's disease. However, the pathway to diagnosing Wilson's disease is highly variable. Follow-up testing depends on results of
initial testing, plus the ability to access relevant tests and the likelihood with which the doctor believes the individual has Wilson's disease.
What are the main results in the review?
We found eight studies (5699 participants), of whom 1009 were diagnosed with Wilson's disease. One study assessed all three biochemical
tests, three assessed caeruloplasmin, one assessed 24-hour urinary copper, two assessed hepatic copper and one assessed both urine
and hepatic copper.
Biomarkers for diagnosis of Wilson's disease (Review)
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Four studies evaluated adults and children, three evaluated children and adolescents and one evaluated adults. The clinical presentation
of Wilson's disease also varied: six studies evaluated individuals with both liver and neurological symptoms of Wilson's disease in addition
to individuals who had not yet developed symptoms; and two studies evaluated individuals with liver symptoms only.
The ability of the three tests evaluated to detect those with Wilson's disease (termed sensitivity) was variable (50% to 94.4%); the ability
to detect those without disease (termed specificity) was also variable (52.2% to 98.3%). No single test was capable of diagnosing Wilson's
disease in isolation. There was also not enough evidence to determine the accuracy of the tests within different age groups or Wilson's
disease subgroups (e.g. those with liver or neurological symptoms).
How reliable are the results of the studies in this review?
Since there is no gold standard test for diagnosing Wilson's disease, we selected a clinical and laboratory standard (the Leipzig criteria)
to determine the diagnosis of the disease. Results of this review suggest that part of the variability in test sensitivity and specificity at the
cut-oJs in the Leipzig criteria is likely to be influenced by the method used to undertake the diagnostic tests. However, there were some
problems with how the included studies were conducted. This may result in the caeruloplasmin, urine or liver copper appearing more
accurate than it is, increasing the number of positive results (sensitivity).
What are the implications of this review?
Limited evidence from the included studies support the use of multiple-index testing as outlined in the Leipzig criteria. The diagnostic
thresholds used in this criteria will vary with laboratory test, with the method used to conduct the laboratory test, and with the individuals
in the included studies (who varied by age, ethnicity and clinical presentation of disease). These factors should therefore be taken into
account when interpreting the results. High sensitivity (true-positive rate) for each of the laboratory tests is possible at particular cut-oJ
values; however, when used in isolation, each laboratory test may have a false-positive or false-negative rate. Limitations in study design
may exaggerate test accuracy.
How up-to-date is this review?
The authors searched for and used studies published up to 29 May 2019.
Biomarkers for diagnosis of Wilson's disease (Review)



































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Summary of findings table - caeruloplasmin
Biomarkers for diagnosis of Wilson's disease
Population: people suspected of WD
Prior testing: Unclear
Setting: outpatients presenting with liver or neurological symptoms, or asymptomatic individuals
Index tests: caeruloplasmin
Target condition: WD
Reference standard: Leipzig criteria
Importance: to determine whether caeruloplasmin used an index test could result in earlier diagnosis and earlier treatment of WD, as well as reduce further necessary test-
ing
Studies: observational (cohort, case-control) studies that assessed the diagnostic accuracy of an index test in the clinical context of the diagnosis of WD


















or rule in WD
Overall methodological quality of included studies was variable with high risk
of bias for participant selection and reference standard and low risk of bias for
index test and flow and timing. Concerns around study design imply that diag-
nostic accuracy figures may not transfer to populations outside of the relevant
study.









or rule in WD
Overall methodological quality of included studies was variable with high risk
of bias for participant selection and reference standard and low risk of bias for
index test and flow and timing. Concerns around study design imply that diag-
nostic accuracy figures may not transfer to populations outside of the relevant
study.































































































































Summary of findings 2.   Summary of findings table - hepatic copper
Biomarkers for diagnosis of Wilson's disease
Population: people suspected of WD
Prior testing: unclear
Setting: outpatients presenting with liver or neurological symptoms, or asymptomatic individuals
Index tests: hepatic copper
Target condition: WD
Reference standard: Leipzig criteria
Importance: to determine whether hepatic copper used an index test could result in earlier diagnosis and earlier treatment of WD, as well as reduce further necessary test-
ing
Studies: observational (cohort, case-control) studies that assessed the diagnostic accuracy of an index test in the clinical context of the diagnosis of WD


















or rule in WD
Overall methodological quality of included studies was variable with high risk
of bias for participant selection and reference standard and low risk of bias for
index test and flow and timing. Concerns around study design imply that diag-
nostic accuracy figures may not transfer to populations outside of the relevant
study.
Abbreviations: WD: Wilson's disease
 
 
Summary of findings 3.   Summary of findings table - 24-hour urinary copper
Biomarkers for diagnosis of Wilson's disease
Population: people suspected of WD
Prior testing: unclear
Setting: outpatients presenting with liver or neurological symptoms, or asymptomatic individuals






























































































































Reference standard: Leipzig criteria
Importance: to determine whether 24-hour urinary copper used an index test could result in earlier diagnosis and earlier treatment of WD, as well as reduce further neces-
sary testing
















96 (1) 0.40 (NA) Single-test strate-
gy inadequate to
rule out or rule in
WD
Overall methodological quality of included studies was variable with high risk
of bias for participant selection and reference standard and low risk of bias for
index test and flow and timing. Concerns around study design imply that diag-












rule out or rule in
WD
Overall methodological quality of included studies was variable with high risk
of bias for participant selection and reference standard and low risk of bias for
index test and flow and timing. Concerns around study design imply that diag-
nostic accuracy figures may not transfer to populations outside of the relevant
study.
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B A C K G R O U N D
Wilson's disease (WD), first described by Samuel Wilson in 1912,
is an autosomal recessive metabolic disorder resulting from mu-
tations in the ATP7B gene which encodes a protein pathway in-
volved in copper hepatic metabolism (Bull 1993; Compston 2009).
This secretory pathway involves both copper excretion into bile
and its incorporation into apocaeruloplasmin for the synthesis of
functional caeruloplasmin (Davis 1996). The disease develops as
a consequence of the accumulation of copper in affected tissues
and therefore hepatic disease presents earlier than neurological
disease (Ferenci 2019).
The diagnosis of WD is often delayed, it may take over three years
due to the non-specific clinical features and the requirement for
combination testing for diagnosis (Ferenci 2019). This delay may
in turn affect outcome and has implications for other family mem-
bers in terms of diagnosis. Recent work has shown that up to 40%
of children but 58% of adults were cirrhotic at diagnosis (Feren-
ci 2019). The diagnosis of WD depends on a combination of clini-
cal, biochemical, histological and genetic testing and analysis. The
Leipzig criteria (Table 1) were established to help standardise diag-
nosis and management of WD (Ferenci 2003). However, it should be
emphasised that these criteria date from 2003, and many of these
have not been formally evaluated; this review examines the evi-
dence behind biochemical testing for WD (Mak 2008).
Target condition being diagnosed
The clinical presentation of WD can vary widely in terms of symp-
toms, signs at presentation and age of onset of such features, with
clinically evident liver disease often preceding neurological disease
by up to a decade (EASL 2012). The key clinical diagnostic features
used to form the basis of the Leipzig criteria include liver disease,
motor and neuropsychiatric disturbances, corneal Kayser-Fleisch-
er (KF) rings and acute haemolysis (in association with acute liver
failure) (Ferenci 2003). The original classical neurological presenta-
tions as described by Wilson, were characterised by a movement
disorder in the setting of characteristic biochemical abnormalities
and often contrast with the non-specific protean hepatic manifes-
tations.
Index test(s)
The most commonly used initial diagnostic test for WD is caerulo-
plasmin, with a concentration of less than 0.2 g/L considered as the
conventional diagnostic cut-oJ (EASL 2012). However, the lower
reference limit can vary with different assay types and age; this may
be reduced in other causes of chronic liver disease, copper defi-
ciency or in protein-losing states. Caeruloplasmin was originally de-
scribed as an acute-phase protein with diverse functions (Hellman
2002). The initial protein produced is an inactive, unstable non-cop-
per bound form, apocaeruloplasmin. Following the addition of cop-
per by ATP7B, the functional more stable product holocaeruloplas-
min is formed. The type of assay used has important implications
for WD diagnosis. Immunoassays are commonly used for measur-
ing caeruloplasmin, and measure both apo- and holocaeruloplas-
min forms; however, caeruloplasmin oxidase-based methods only
measure the holocaeruloplasmin form. Therefore, immunoassays
may theoretically lead to an overestimate as compared with the
caeruloplasmin oxidase-based method. However, the lack of wide-
spread availability of the oxidase method limits it's use (Gnanou
2006; Walshe 2003).
Turbidimetry and nephelometry are common immunoassay meth-
ods used to measure many plasma proteins including caeruloplas-
min (Tietz 2012a). In principle an individual's sample is added to
a combination of assay reagent and antibodies to the analyte or
antigen of interest (in this case caeruloplasmin), which results in
precipitation of an immune complex that increases the turbidity
(cloudiness) of the sample. By shining a light through the sample
and with appropriate calibration, the level of analyte can be de-
termined. In turbidimetry the absorbance of the light by the sam-
ple is measured, whereas in nephelometry the light scatter is mea-
sured at a fixed angle. In general the analyte concentration is in-
versely proportional to the transmitted light signal. Published da-
ta, based on UK external quality assurance scheme results, have
shown that for caeruloplasmin (depending on chosen method)
the same sample may vary +/-20% depending on the chosen im-
munoassay method; with Olympus, Roche Intergra showing a neg-
ative bias and Beckman Immage, Dade Behring, Abbott platforms
showing a positive bias (Zegers 2013).
24-hour urinary copper studies are often used as a follow-up to ab-
normal caeruloplasmin testing. In the absence of renal impairment,
urinary copper reflects the amount of non-caeruloplasmin bound
copper. Cut-oJ values of more than 1.2 times the upper limit of nor-
mal (ULN) or more than 2 ULN have been suggested as indicating
possible WD (EASL 2012). Use of such cut-oJ values is problemat-
ic and method-dependent, with up to 25% of people with WD (es-
pecially children) having urinary copper levels less than this (Nicas-
tro 2010). Urinary copper excretion may also be increased in other
causes of chronic liver disease (LaRusso 1976).
Hepatic copper accumulation is the hallmark and earliest manifes-
tation of WD. Copper distribution within hepatic parenchyma may
not be homogenous, may be susceptible to sampling error by biop-
sy and may be elevated in other liver disorders, particularly those
involving cholestasis (Roberts 2008). Cut-oJ values have been sug-
gested, but again these are method-dependent and as yet not ful-
ly validated (EASL 2012). The use of specific stains, e.g. rhodamine
or orcein, reveal focal copper deposition in less than 10% as these
stains only detect lysosomal deposition. Previous studies have sug-
gested that a level of hepatic copper greater than 4 µmol/g is con-
sidered the best evidence for a diagnosis of WD; however, there is
some evidence that such a threshold may need to be lower in order
to increase sensitivity (Yang 2015).
Two of the more common techniques that are used to measure
urinary and hepatic copper are atomic absorption and inductive-
ly coupled plasma mass spectrometry. Atomic absorption spec-
troscopy uses the absorption of light to measure the concentra-
tion of gas phase atoms, which is achieved by vaporising copper in
a flame. The atoms absorb the energy generated from the flame,
making transition to higher energy levels with the copper concen-
tration being determined from the amount of absorption (Tietz
2012b). Inductively coupled plasma mass spectrometry combines
a high temperature source (inductively coupled plasma (ICP)) with
a mass spectrometer. The ICP converts the atoms of the relevant el-
ement in the sample, in this case copper, to ions and these ions are
separated and detected using mass/charge ratio by a mass spec-
trometer (Tietz 2012c). This has been shown to be more sensitive
than atomic absorption with lower limits of detection, larger linear
range and is increasingly become the method of choice to measure
trace elements such as copper. Again, associating any cut-oJ val-
ue with the relevant method is important for urinary copper, with
Biomarkers for diagnosis of Wilson's disease (Review)
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the recent UK trace element quality assurance scheme showing a
variability of +/-17% depending on the choice of atomic absorption
or ICP mass spectrometry (UK NEQAS 2018). Unfortunately, due to
limited sample availability, such schemes are not available for he-
patic copper to show inter-assay variability.
Clinical pathway
In the original paper outlining the Leipzig criteria, there is no agreed
clinical reference standard pathway for the diagnosis of WD, and
hence this has not been documented (Ferenci 2003). There is a di-
agnostic algorithm in the European Association for the Study of the
Liver (EASL) guidelines on WD, but again this is not a complete path-
way that outlines test selection and stages of testing proceeding
to diagnosis (EASL 2012). The EASL guidelines do comment that a
combination of tests are required and that, reflecting the challenge
of diagnosing WD, no single clinical sign or laboratory test is diag-
nostic in isolation.
A recent cohort study of 1359 people with WD has helped improve
our understanding of how WD presents clinically (Ferenci 2019).
The study participants were 702 children and 655 adults (679 males
and 678 females). Initially, the authors discovered an asympto-
matic hepatic involvement, which may progress and become symp-
tomatic with 39.5% of children and 58% of adults affected with
cirrhosis. Neurological disease occurred later and was more com-
mon in males, with hepatic disease being more common in females.
Overall, the mean age for presentation with chronic liver disease
was 17.8 years, for decompensated cirrhosis was 25.9 years, and
for those with a neurological presentation was 23.8 years. The au-
thors also noted that delays of over three years for diagnosis were
not uncommon and that often individuals were diagnosed follow-
ing an initial presentation with asymptomatic aminotransferase el-
evation (Ferenci 2019).
The mainstay of WD therapy is copper chelation (e.g. penicillamine)
or medication that interferes with copper absorption, such as zinc
(Członkowska 2018). Those individuals with cirrhosis may be con-
sidered candidates for hepatic transplantation. Medical treatment
for WD is lifelong, with success being dependent on clinical fea-
tures at presentation, with more than 90% improvement in those
treated before advanced liver disease or neurological involvement,
dropping to 50% in those with neurological disease at presentation
(EASL 2012).
Alternative test(s)
This autosomal recessive disorder of copper transport is due to mu-
tations in the ATP7B gene. The worldwide prevalence of WD has pre-
viously been cited as 1 in 30,000, with a carrier frequency of 1 in
90; however, these figures pre-date the discovery of the ATP7B gene
and more recent work has cited a higher frequency of 1 in 7000 for
genetic diagnosis (Coffey 2013). Following extensive linkage and
positional cloning studies, the ATP7B gene was located on chromo-
some 13q14.3 (Bull 1993). The gene has 21 exons with more than
10000 base pairs. The molecular analysis of individuals and families
affected by WD have demonstrated that, to date, there are up to 500
disease-causing mutations (Coffey 2013).
The problem with the collation of such mutations and variants is
the lack of control participants tested in studies, which then inac-
curately reported new variants. Recommendations of a minimum
of 100 normal chromosomes from the same ethnic population to
be tested are often not followed (Kenney 2007). Whilst most of the
pathogenic mutations discovered to date are rare and only report-
ed in single families, some of these are more common and account
for large numbers of WD cases. Most affected individuals are com-
pound heterozygotes. These mutations mainly affect the trans-
membrane region and largely consist of missense and stop muta-
tions (Kenney 2007; Thomas 1995). However, strict genotype-phe-
notype remains unproven, even within families; and therefore, oth-
er genetic modifiers are believed to be at play (Czlonkowska 2009;
Huster 2012). A recent study by Ferenci evaluating 1359 people with
WD failed to show any link between genotype and clinical presen-
tation, suggesting that factors such as age and sex are more impor-
tant in how individuals present (Ferenci 2019).
In the presence of definite clinical or biochemical abnormalities,
the identification of only one of the two disease-causing genes
may be adequate to confirm diagnosis. However, if the significance
of the initial identified mutation is doubtful, the second mutation
should be identified (EASL 2012). It should be noted that in order
to infer pathogenicity, a mutation must clearly be disease-causing
and not just a common missense variant. Hence, the importance of
normal ethnic controls. Developments in next-generation sequenc-
ing may allow faster sequencing and better coverage; however,
large numbers of variants of uncertain significance may be generat-
ed and relevant standardised functional methods to test these re-
main to be clearly established.
As discussed earlier, it is the failure of incorporation of copper
into its carrier proteins the leads to low caeruloplasmin and low
serum copper, however, the proportion of unbound copper is in-
creased. Historically, this was calculated as non-caeruloplasmin
copper (NCC (µmol/L) = total copper (µmol/L) - n(µmol/mg) x ceru-
loplasmin (mg/L) where n is the factor for copper bound/mg of
ceruloplasmin) as it was not possible to measure this (Twomey
2005). This NCC was used for diagnosing and managing people with
WD on chelation therapy. However, recent work has questioned the
variability and reliability of NCC for both diagnosis and therapeu-
tic monitoring (Duncan 2016; Pfeiffenberger 2019). The latter study
concluded that for therapeutic monitoring, NCC offered no benefit
over 24-hour urine copper alone.
Exchangeable copper and its derived relative exchangeable copper
(REC) have recently been proposed as a new biomarker for diag-
nosing WD as a method of measuring free copper described above.
Specfically, REC has been shown to provide a high sensitivity and
specificity for WD (El Balkhi 2011). The exchangeable copper corre-
sponds to the labile fraction of copper bound mainly to albumin as
well as free unbound copper. An increase in this fraction above nor-
mal is thought to reflect a blood and tissue copper overflow into
the blood due to hepatic damage. This test has, however, only been
evaluated in small groups and further validation will be required,
particularly its specificity in other causes of chronic liver disease.
The convenience of a reliable serum marker for diagnostic purpos-
es is highly desirable for use in WD work up. A follow-up paper by
the same group has shown that exchangeable copper may be of
use in differentiating neurological from hepatic WD, with those hav-
ing neurological WD having higher exchangeable copper (Poujois
2017).
A key clinical feature in the diagnosis of WD is the presence of KF
rings, occurring in 100% of individuals with neurological disease
and less frequently in those with liver disease (Taly 2007). The phe-
nomenon arises as a consequence of copper deposition in the De-
scemets membrane and indicates that free copper has been re-
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leased into the individual's circulation. Visualisation requires the
use of slit-lamp amplification (Walshe 2011).
Due to the invasive nature of liver biopsy, this is no longer common-
ly undertaken for routine diagnosis of WD; previous studies have
shown that up to 40% of individuals at presentation may have cir-
rhosis (Merle 2007). Early histological changes of WD are non-spe-
cific and represent a spectrum that may include hepatic steatosis,
chronic hepatitis and fibrosis and may add to diagnostic delay.
Acute liver failure due to WD is an important diagnosis to make ear-
ly, affecting both the management of the individual and also en-
abling screening and diagnosis of other family members (Ostapow-
icz 2002). Acute hepatic failure in WD gives rise to many characteris-
tic biochemical and haematological abnormalities, due to the toxic
effect of an acute copper release from hepatocyte lysis. The labora-
tory findings of fulminant WD previously described have included
Coomb's negative haemolytic anaemia, low serum alkaline phos-
phatase and increased aspartate to alanine aminotransferase ra-
tios (Berman 1999; Korman 2008; Lee 1998; Wilson 1987).
Rationale
Consensus guidelines for diagnosing WD exist. However, many of
the criteria have not been formally evaluated and issues such as
sensitivity and specificity for index tests remain to be fully explored.
O B J E C T I V E S
To determine the diagnostic accuracy of the index tests for WD. The
index tests covered by this Cochrane Review are caeruloplasmin,
24-hour urinary copper and hepatic copper content.
Secondary objectives
We have two main secondary objectives, to investigate whether in-
dex tests should be performed in all individuals who have been rec-
ommended for testing for WD and whether these tests should be
limited to subgroups of individuals (see Methods investigation of
heterogeneity). We discuss differences in cut-oJ values and assay
types as these are likely to have the most influence on heterogene-
ity. We anticipated that the study reports and number of papers
selected would lack the necessary detail and volume to undertake
meaningful subgroup analysis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included observational (cohort, case-control) studies that as-
sessed the diagnostic accuracy of an index test in the clinical con-
text of the diagnosis of WD. These studies included those with WD
or suspected WD versus a normal population but also included het-
erozygotes where genetic testing was available. We excluded stud-
ies that evaluated the index test in a normal population without a
WD comparator group or in use of diseases other than WD.
Participants
Children and adults of all ages with suspected WD evaluated by the
Leipzig criteria were eligible for inclusion (Ferenci 2003). Studies
that did not use the Leipzig criteria or failed to define how WD was
defined and those with the acute fulminant form were excluded.
Index tests
The diagnostic accuracy of caeruloplasmin, urinary copper and liv-
er copper content was evaluated for diagnosing WD. The thresholds
for a positive score of each of these index tests, according to the
Leipzig criteria, are provided in an additional table (Table 1).
Target conditions
WD as defined by the Leipzig criteria (Ferenci 2003); details are pre-
sented in an additional table (Table 1).
Reference standards
The clinical reference standard is the diagnosis of WD as outlined
by the Leipzig criteria (Ferenci 2003).
Search methods for identification of studies
We searched for all relevant published and unpublished studies
without restrictions on language, year or publication status.
Electronic searches
We searched for relevant studies from the Cochrane Cystic Fibrosis
and Genetic Disorders Group's Inborn Errors of Metabolism Trials
Register using the term: Wilson*:kw.
The Inborn Errors of Metabolism Trials Register is compiled from
electronic searches of the Cochrane Central Register of Controlled
Trials (CENTRAL) (updated with each new issue of The Cochrane
Library), weekly searches of MEDLINE and the prospective hand-
searching of one journal - Journal of Inherited Metabolic Disease.
Unpublished work is identified by searching through the abstract
books of the Society for the Study of Inborn Errors of Metabolism
conference and the SHS (Scientific Hospital Supplies) Inborn Error
Review Series. For full details of all searching activities for the reg-
ister, please see the relevant section of the Cochrane Cystic Fibrosis
and Genetic Disorders Group's website.
Date of last register search: 29 May 2019.
We also searched the following databases and trial registries:
• Cochrane Central Register of Controlled Trials (CENTRAL; 2017
Issue 8) and Cochrane Database of Systematic Reviews (CDSR)
in the Cochrane Library www.cochranelibrary.com (searched 29
May 2019);
• PubMed (www.ncbi.nlm.nih.gov/pubmed (1946 to 29 May 2019);
• CINAHL EBSCO (1982 to 29 May 2019);
• Embase Ovid (1982 to 29 May 2019);
• Science Citation Index via the Web of Science (1898 to 29 May
2019);
• Web of Science’s Conference Proceedings Citation Index (CPCI;
1900 to 29 May 2019);
• British Library’s ZETOC (zetoc.jisc.ac.uk/wzgw?db=etoc; 1993 to
29 May 2019) for conference abstracts;
• PROSPERO (International Prospective Register of Systematic
Reviews www.crd.york.ac.uk/prospero/search.asp; searched 29
May 2019);
• US National Institutes of Health Ongoing Trials Register Clinical-
trials.gov (www.clinicaltrials.gov; searched 29 May 2019);
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• World Health Organization International Clinical Trials Registry
Platform (WHO ICTRP) (apps.who.int/trialsearch; searched 29
May 2019).
For details of our search strategies, please see Appendix 1.
Searching other resources
The reference lists of all included articles and relevant systemat-
ic reviews were reviewed to identify additional studies not found
through the electronic review.
Data collection and analysis
Selection of studies
Two authors (AR, OT) independently reviewed the titles and ab-
stracts of articles found in the Electronic searches for potential-
ly eligible studies for review. The same two authors independent-
ly assessed full manuscripts against the inclusion criteria and dis-
crepancies were resolved by discussion. We present a PRISMA (Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analyses)
flow diagram to outline the decision-making process for including
studies in the review (Figure 1; PRISMA 2009).
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Figure 1.   Study flow diagram.
 
Data extraction and management
Two authors (AR, SN) independently extracted the following da-
ta from published articles using a pre-determined extraction form,
with discrepancies being resolved by discussion.
• First study author and year (of primary reference)
• Study eligibility
• Participant and method characteristics
• Number of participants
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• Clinical and demographic characteristics (age, clinical presenta-
tion (hepatic versus neurological), ethnicity)
• Details of index text (assay type, control, cut-oJ values)
• Details of the reference standard
• Methodological quality of included studies
We created 2 x 2 tables for each method of the index test described
in this review, cross-tabulating index test results with presence of
the target condition (reference standard), please refer to the rele-
vant appendix for the the format.
The data extraction form incorporated a quality assessment sec-
tion comprising items from Quality Assessment of Diagnostic Accu-
racy Studies-2 (QUADAS-2) (Whiting 2011).
Where a study did not present all relevant data for creating a 2 x 2
table, we planned to contact the study authors directly to request
this information. If study authors were unable to provide the infor-
mation, we planned to retain the study in the narrative section of
the review, but not include it in any meta-analysis.
Assessment of methodological quality
Two authors (AR, SN) independently assessed the methodological
quality of each included study using the QUADAS-2 tool (Whiting
2011) as recommended by Cochrane. We resolved any disagree-




• participant flow and timing.
We assessed each domain in terms of risk of bias, with the first
three domains also considered in terms of applicability concerns.
We present review-specific signalling questions and appropriate
terms concerning the applicability of primary studies related to this
review, together with guidance about ratings, in an appendix (Ap-
pendix 2).
Statistical analysis and data synthesis
For all included studies, we used the data in the 2 x 2 tables to cal-
culate two statistics for each index test in each study, as detailed
above.
For the definitions of all abbreviations used in this section, please
see the table below.
Sensitivity = number of TP / number of participants with the target
condition present (TP + FN). The higher the sensitivity of a test at a
particular cut oJ value, the better the test is at correctly identifying
individuals who have the target condition.
Specificity = number of TN / number of participants without the tar-
get condition present (TN + FP). The higher the specificity of a test
at a particular cut oJ value, the better the test is at correctly iden-
tifying individuals who do not have the target condition.
LR+ = sensitivity/1-specificity. This is the ratio of TP to FP for a par-
ticular test at a particular cut oJ value with LR+ greater than 1 being
preferred.
LR- = 1-sensitivity/specificity. This is the ratio of FN to TN for a par-
ticular test at a particular cut oJ value with LR- closer to 0 being
preferred.
PPV = number of TP/number of TP+FP. This measures the probabil-
ity that a person with a positive test result has the disease.
NPV = number of TN/number of TN+FN. This measures the proba-
bility that a person with a negative test result does not have the dis-
ease.
We intended that these estimates would be used to create ROC and
forest plots for all studies, however given the heterogeneity of index
tests and cut-oJs used in the identified studies, we consider that it
is more appropriate to describe the above statistics narratively.
Given the lack of validated cut-oJs of the index tests (see Index
tests), we expected variability in cut-oJ points chosen in the includ-
ed studies. As this review uses a clinical reference standard based
on the Leipzig criteria, we propose to record diagnostic accuracy
figures for each index test where available in each of the studies
evaluated. Other cut oJ values based on ROC curve analysis evalu-
ated in each of the studies will also be considered.
Therefore, we proposed to meta-analyse pairs of sensitivity and
specificity using the HSROC model (Rutter 2001), which would al-
low for the possibility of variation in threshold between studies,
while also accounting for variation within and between studies and
any potential correlation between sensitivity and specificity. How-
ever, the number of studies for each index test method was limit-
ed and the methods used for the Index test assays were varied (see
Table 2). Therefore, we deemed that it was not appropriate to pool






HSROC hierarchical summary receiver operating characteristic
LR+ positive likelihood ratio
LR- negative likelihood ratio
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NPV negative predictive value
PPV positive predictive value





We planned to investigate the following subgroups:
• age (to include all ages);
• gender;
• ethnicity;
• clinical features (pre-symptomatic, hepatic and or neurologi-
cal);
• index test method;
• different study designs.
In exploratory analyses, we planned to visually examine forest plots
of sensitivity and specificity for each index test, and summary ROC
plots to explore the effect of each of the factors of interest. If there
were sufficient studies, we planned to perform meta-regression by
including each potential source of heterogeneity as a covariate in
the HSROC model. However, again we were unable to carry out our
planned analyses owing to an insufficient number of studies and
heterogeneous nature of the index test methods which could not
be combined in meta-analyses.
Sensitivity analyses
If appropriate, we planned to perform sensitivity analyses exclud-
ing studies which are at a high risk of bias for at least one domain
of the QUADAS-2 tool (see Assessment of methodological quality).
Again, given the small number of studies, we did not attempt to per-
form any sensitivity analyses.
Assessment of reporting bias
We did not formally plan to investigate reporting bias via exist-
ing analytical tools such as funnel plots due to current uncertain-
ty around interpretation of such tools in this setting. Instead, we
performed systematic electronic searches and detailed searches
of other published and unpublished sources (see relevant sections
above) in order to retrieve as many eligible studies as possible for
inclusion in the review.
Summary of findings of the review
We have summarised the results of the review for each index test in
a summary of findings table for pre-specified thresholds of each in-
dex test, based on the clinical reference standard (Leipzig criteria)
(Summary of findings table 1; Summary of findings table 2; Sum-
mary of findings table 3). The tables summarise the following infor-
mation: threshold, summary and accuracy, number of participants
and studies, prevalence, implications, quality and comments.
R E S U L T S
Results of the search
Out of 10,638 records (following removal of duplicates), we exclud-
ed 10,616 clearly irrelevant records. We obtained and scrutinised a
total of 20 full-text reports to assess their eligibility for inclusion in
this review and two further reports await classification (Aksu 2018;
Zhou 2019) as illustrated in the PRISMA flow diagram (Figure 1). We
excluded 12 studies which did not meet the eligibility criteria and
have provided details of the reasons for exclusion of each of these
studies in the characteristics of excluded studies table. In brief a
common reason for exclusion was the fact that studies failed to de-
fine how participants were diagnosed with WD or did not use the
Leipzig criteria for WD case definition (Causa 1997; Frommer 1981;
Gibbs 1979; Gnanou 2006; Lech 2007; Li 1983; Liggi 2013; Mahjoub
2012; Markowitz 1955; Mzhel'skaia 1994). Another common reason
was that the method used in the paper were not index tests in the
current review (Prasad 1998; Siotto 2014).
We have included eight studies in the review, however, due to the
limited number of studies and methodological differences such as
use of different thresholds, we have been unable to undertake any
meta-analysis (Ferenci 2005; Mak 2008; Merle 2009; Lu 2010; Nicas-
tro 2010; Sezer 2014; Yang 2015; Xu 2018). These studies were case-
control or cross-sectional in nature, evaluating sensitivity, speci-
ficity, positive and negative predictive value of the particular test
for the diagnosis of WD.
Four studies evaluated hepatic copper using flame atomic absorp-
tion spectroscopy (Ferenci 2005; Nicastro 2010; Sezer 2014; Yang
2015), three evaluated caeruloplasmin using nephelometry (Mak
2008; Merle 2009; Xu 2018) and one using radial immunodiffusion
(Nicastro 2010). Two studies evaluated 24-hour urine copper using
atomic absorption spectroscopy (Nicastro 2010; Sezer 2014), an-
other study used inductively coupled mass spectrometry (Lu 2010).
The characteristics of the included studies are summarised in an
additional table (Table 2).
Methodological quality of included studies
We judged the studies to be of overall low risk of bias in two of the
domain categories of QUADAS-2 (index test, and flow and timing)
and to be of high risk of bias for the domains patient selection and
reference standard (Figure 2; Appendix 2).
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Figure 2.   Risk of bias and applicability concerns graph: review authors' judgements about each domain presented
as percentages across included studies
 
The main concern was around participant selection bias with con-
venience sampling being the most common method of participant
selection. However, this is not uncommon in clinical studies par-
ticularly with uncommon diseases such as WD where considerable
time may be taken for both diagnosis and to build up positive di-
agnoses. At the same time, more detail regarding phenotype of
cases (beyond generic hepatic or neurological) and controls (to in-
clude severity-synthetic function in those with chronic liver dis-
ease) would assist with mitigating this selection bias.
Due to the nature of testing for WD which depends on clinical, bio-
chemical and genetic results to generate the Leipzig score, there is
potentially a risk of bias being aware of the clinical reference stan-
dard prior to the conduct of the index test. However, this risk is
heavily dependent on the subjective nature of the index test which
does not apply to quantitative biochemical testing evaluated in this
review. For seven of the eight studies, threshold values were pre-
specified prior to analysis as outlined for each index test under the
Leipzig criteria. The importance of this is that pre-specification lim-
its potential for over fitting diagnostic accuracy figures that can lim-
it external validity of the study. For one study there was no pre-
specified index test threshold and cut-oJ value was optimised after
analysis of the index test and on the basis of this has been classified
as high risk bias for index test part of QUADAS-2 (Merle 2009) (Figure
2; Appendix 2).
The biochemical index tests evaluated in this review contribute to
the Leipzig score of each of the participants evaluated in the rele-
vant study. As a consequence of being a clinical reference standard
prior knowledge of the index result is likely to have occurred in or-
der to generate the Leipzig score. As outlined in this review no sin-
gle biochemical diagnostic test is capable of diagnosing WD in isola-
tion. The Leipzig criteria depends on a combination of clinical, bio-
chemical and genetic testing. Closer inspection of the Leipzig crite-
ria (Table 1) shows that one test (mutational analysis) on its own
had potential to bias the Leipzig testing pathway, which could (for
a mutation on two chromosomes) generate a score of four, which
establishes a WD diagnosis and thus could in theory stop further
testing. This, however, under appreciates that clinicians using the
Leipzig score pathway will have to use combination testing gener-
ally to make a diagnosis and none of the biochemical testing would
have the same effect as genetic testing in terms of potential bias.
That being said, we acknowledge that some of the criteria for the
Leipzig criteria are subjective, namely the clinical and histological
criteria and that as a consequence, knowledge of these test results
prior calculating the Leipzig score could bias the more subjective
elements of the Leipzig criteria.
We grouped QUADAS-2 quality assessment items into four do-
mains: participant selection, index test, reference standard, flow
and timing. The main source of bias arose from patient selection
and reference standard as discussed above (see Figure 2 and Ap-
pendix 2).With regard to flow and timing, whilst specific percent-
age of follow-up was not calculated for most, it was easy to follow
participants to study completion. Therefore, it is unlikely that there
were enough losses to follow up to have introduced significant bias.
Findings
Eight studies met the eligibility criteria and we have included them
in the review (Ferenci 2005; Mak 2008; Merle 2009; Lu 2010; Nicastro
2010; Sezer 2014; Yang 2015; Xu 2018). Details of these studies can
be found in the tables (Characteristics of included studies; Table 2).
Below we narratively summarise review findings including details
of the study populations, the analyte measured, the assay used and
the diagnostic test accuracy results for all reported thresholds by
study.
Index test - caeruloplasmin
Five studies evaluated various thresholds of ceruloplasmin (4281
participants, of whom 541 had WD) (Mak 2008; Merle 2009; Nicastro
2010; Sezer 2014; Xu 2018). Three studies were based in Europe (one
in Germany (Merle 2009), one in Italy (Nicastro 2010), one in Turkey
(Sezer 2014)) and two in China (Mak 2008; Xu 2018). Two studies
were conducted in children (Nicastro 2010; Sezer 2014), one in an
adult population (Merle 2009) and two in children and adults (Mak
2008; Xu 2018).
Cut-oJs defined by the Leipzig criteria (0.1 g/L and 0.2 g/L) (Table
1), were reported by four of the five studies (Mak 2008; Nicastro
2010; Sezer 2014; Xu 2018) and four of the studies reported other
thresholds ranging from 0.14 g/L to 0.19 g/L, mostly determined as
the 'optimal' or 'most useful' threshold by ROC curve analysis (Mak
2008; Merle 2009; Nicastro 2010; Xu 2018). Sensitivity and specificity
results for all thresholds are presented in a figure (Figure 3); 2 x 2 ta-
bles, sensitivity, specificity, PPV, NPV, LR+ and LR- for all thresholds
are presented in an additional table (Table 3) and the results for the
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cut-oJs defined by the Leipzig criteria are presented in a summary
of findings table (Summary of findings 1).
 
Figure 3.   Forest plot of tests: 1 Caeruloplasmin (Leipzig criteria threshold 0.1g/L), 2 Caeruloplasmin (Leipzig criteria
threshold 0.2g/L), 3 Caeruloplasmin (other threshold 0.14g/L), 4 Caeruloplasmin (other threshold 0.15g/L), 5
Caeruloplasmin (other threshold 0.18g/L), 6 Caeruloplasmin (other threshold 0.19g/L).
 
One study by Mak evaluated the cut-oJs for ceruloplasmin used
by the Leipzig criteria in a mixed clinical (hepatic and neurologi-
cal) population of children and adults (Table 1) (Mak 2008). Serum
caeruloplasmin was measured using nephelometry, with testing in
59 people with WD pre-treatment, 71 family members (49 heterozy-
gotes, 22 wild type homozygotes), a validation group of 25 with sus-
pected WD and 690 normal controls. The age range in people with
WD was 4 years to 50 years. For the cut-oJs used in the Leipzig crite-
ria 0.2 g/L and 0.1 g/L, sensitivity was 98.3% (95% CI 90.6% to 100%)
and 78.9% (95% CI 66.1% to 88.6%), respectively (Mak 2008). Speci-
ficity was 55.9% (95% CI 47.1% to 64.4%) and 100% (95% CI 97.3%
to 100%), respectively (Table 3). ROC curve analysis conducted in
this study showed that a cut-oJ of 0.14 g/L gave maximal sensitivi-
ty and specificity with an area under the ROC curve of 0.99 (95% CI
0.97 to 1.01). We constructed a 2 x 2 table based on this cut-oJ and
calculated diagnostic test accuracy statistics (Table 3).
In the Merle study, caeruloplasmin measured by caeruloplasmin
oxidase, was compared with that as measured by nephelometry in
110 people with WD with mixed clinical features (71 hepatic, 29 neu-
rological, 10 pre-symptomatic), 52 healthy controls and 51 with cir-
rhosis not due to WD (Merle 2009). Median age of people with WD
was 37 years (IQR 27 to 46.5), 45 were male (40.9%) and 65 were
female (59.1%). Diagnosis was based on the Leipzig criteria, on-
ly adults were evaluated and within the WD group 14 were treat-
ment-naive. As ceruloplasmin oxidase is not part of the Leipzig cri-
teria (Table 1) this will not be considered further and hence the find-
ings recorded from this study relate to caeruloplasmin measured
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by nephelometry. The study authors did not quote diagnostic accu-
racy figures for caeruloplasmin as quoted in the Leipzig criteria but
did undertake ROC curve analysis to generate a a cut-oJ with maxi-
mal sensitivity and specificity. ROC curve analysis conducted by the
study authors for the 110 people with WD, 52 healthy controls and
51 with cirrhosis not due to WD, showed that a cut-oJ of 0.19 g/L
gave maximal sensitivity and specificity with an area under the ROC
curve of 0.93 (95% CI 0.897 to 0.962) (Merle 2009). We constructed
a 2 x 2 table based on this cut-oJ and calculated diagnostic test ac-
curacy statistics comparing the WD group with those with cirrhosis
not due to WD (Table 3).
In the Nicastro study, 40 children with treatment-naive WD (ele-
vated transaminases or family screening) and 58 age- and gen-
der-matched controls with non-WD-related chronic liver disease
were evaluated (Nicastro 2010). In the WD group there were 26
males, 14 females, age range 1.1 to 20.9 with a median of 6.1 years.
Caeruloplasmin was measured by radial-immunodiffusion, WD was
defined by the Leipzig criteria (Table 1). ROC curve analysis con-
ducted by the authors showed that a cut-oJ of 0.2 g/L gave maximal
sensitivity and specificity with an area under the ROC curve of 0.94
(95% CI 0.88 to 0.99) (Table 3). This cut-oJ is also one of the caerulo-
plasmin cut-oJs used in the Leipzig criteria (Table 1). We construct-
ed a 2 x 2 table based on this cut-oJ and calculated diagnostic test
accuracy statistics: sensitivity 95.0% (95% CI 83.1% to 99.4%); and
specificity 82.8% (95% CI 70.6% to 82.2%) (Table 3).
The Sezer study was conducted in a paediatric population with 35
children with WD (treatment-naive) as defined by the Leipzig crite-
ria (Table 1) and 41 age, gender matched with non-WD chronic liver
disease (Sezer 2014). In the WD group mean age was 10.2 years, with
a range of 8 years to 16.5 years and 57.1% (20) were male and 42.9%
(15) were female. Serum caeruloplasmin was measured using im-
muno-turbidimetry. At the 0.2 g/L cut oJ used in the Leipzig criteria
(Table 1), sensitivity was 77.1% (95% CI 59.9% to 89.6%) and speci-
ficity 65.9% (95% CI 49.4% to 79.9%) (Table 3). The authors conclud-
ed that they did not undertake ROC curve analysis to define a clear
cut-oJ due to overlap in caeruloplasmin values between WD and
non-WD group, with 22% in the former group > 0.2 g/L and 29% in
the latter group < 0.2 g/L (Sezer 2014).
In the Xu study both children and adults with ceruloplasmin be-
ing measured by nephelometry in 297 with WD (hepatic, neurolog-
ical, pre-symptomatic), 3751 with non-WD (chronic liver disease,
nephrotic syndrome, movement disorders) (Xu 2018). The mean
age of the participants at diagnosis was 21.8 years with a range of
2 years to 62 years. At the 0.2 g/L cut-oJ used in the Leipzig criteria
(Table 1) (also presented by the study authors), sensitivity was 99%
(95% CI 97.1% to 99.8%) and specificity was 80.9% (95% CI 79.6%
to 82.2%) (Table 3). ROC curve analysis conducted by the authors
showed that a cut-oJ of 0.15 g/L gave maximal sensitivity and speci-
ficity with an area under the ROC curve of 0.992 (95% CI 0.987 to
0.996) (Xu 2018). We constructed a 2 x 2 table based on this cut-oJ
and calculated diagnostic test accuracy statistics (Table 3).
Index test - hepatic copper
Four studies evaluated various thresholds of hepatic copper (1150
participants, of whom 367 had WD) (Ferenci 2005; Nicastro 2010;
Sezer 2014; Yang 2015). Three studies were conducted in Europe
(one in Austria (Ferenci 2005), one in Italy (Nicastro 2010) and one
in Turkey (Sezer 2014)) and one study was conducted in China (Yang
2015). Two were conducted in children (Nicastro 2010, Sezer 2014)
and two in children and adults (Ferenci 2005; Yang 2015).
The cut-oJ defined by the Leipzig criteria (> 4 μmol/g, see Table
1) was reported by all four studies (Ferenci 2005; Nicastro 2010;
Sezer 2014; Yang 2015) and three of the four studies reported oth-
er thresholds ranging from 1.2 μmol/g to 3.3 μmol/g, mostly de-
termined as the 'optimal' or 'most useful' threshold by ROC curve
analysis (Ferenci 2005; Nicastro 2010; Sezer 2014; Yang 2015). Sen-
sitivity and specificity results for all thresholds are presented in a
figure (Figure 4); 2 x 2 tables, sensitivity, specificity, PPV, NPV, LR+
and LR- for all thresholds are presented in an additional table (Ta-
ble 4) and the results for the cut-oJs defined by the Leipzig criteria
are presented in a summary of findings table (Summary of findings
2).
 
Biomarkers for diagnosis of Wilson's disease (Review)









Cochrane Database of Systematic Reviews
Figure 4.   Forest plot of tests: 7 Hepatic copper (Leipzig criteria threshold >4 μmol/g), 8 Hepatic copper (other
threshold 1.2 μmol/g), 9 Hepatic copper (other threshold 1.5 μmol/g), 10 Hepatic copper (other threshold 3.3 μmol/
g).
 
In the Ferenci study, hepatic biopsy pre-treatment was undertaken
in a mixed clinical population (83 hepatic, 34 neurological, 18 pre-
symptomatic) of children and adults (Ferenci 2005). There were 114
people with WD confirmed by the Leipzig criteria in whom copper
content was measured (Table 1); these people were compared with
26 normal controls and 219 people with chronic liver disease (in-
cluding hepatitis C, non-alcoholic liver disease, alcoholic liver dis-
ease, autoimmune hepatitis, Budd-Chiari syndrome, haemochro-
matosis). Hepatic copper content was measured using flame atom-
ic absorption spectroscopy (Kingston 1986) and did not differ on
the basis of age or mode of clinical presentation. At the pre-speci-
fied cut-oJ for hepatic copper of 250 μg/g (4 μmol/g), which is the
cut oJ used in the Leipzig criteria (Table 1), sensitivity was 83.3%
(95% CI 75.2% to 89.7%), specificity was 98.6% (95%CI 96.1% to
99.0%) (Table 4). ROC curve analysis conducted by the study au-
thors showed increased sensitivity for detecting WD by reducing
cut-oJ to 1.2 μmol/g, with an area under the ROC curve of 0.98
(95% CI 0.979 to 0.996) (Ferenci 2005). We constructed a 2 x 2 table
based on this cut-oJ and calculated diagnostic test accuracy statis-
tics (Table 4).
As stated above, in the Nicastro study, 40 children with treat-
ment-naive WD (elevated transaminases or family screening) and
58 age- and gender-matched controls with non-WD-related chron-
ic liver disease were evaluated (Nicastro 2010). In the WD group
there were 26 males and 14 females; age range was 1.1 years to 20.9
years, with a median of 6.1 years. Hepatic copper was measured
by atomic absorption spectroscopy. The authors did not undertake
ROC analysis for hepatic copper, however, based on figures provid-
ed in the paper at the cut-oJ of > 4 μmol/g (as used in the Leipzig
criteria) (Table 1), we constructed a 2 x 2 table and calculated di-
agnostic test accuracy statistics: sensitivity 93.3% (95% CI 77.9% to
99.2%); and specificity 52.2% (95% CI 37.0% to 67.1%) (Table 4).
The Sezer study was conducted in 35 children with WD (treat-
ment-naive) as defined by the Leipzig criteria (Table 1) and 41 age-
and gender-matched controls with non-WD-related chronic liver
disease (Sezer 2014). In the WD group, mean age was 10.2 years
with a range of 8 years to 16.5 years and 57.1% (20) male, 42.9%
(15) female. Hepatic copper was measured by atomic absorption
spectroscopy. At the cut-oJ of 4 μmol/g for hepatic copper used in
the Leipzig criteria (Table 1), sensitivity was 65.7% (95% CI 47.8%
to 80.9%) and specificity was 75.6% (95% CI 59.7% to 87.6%). ROC
curve analysis conducted by the authors showed that a cut-oJ of
1.5 μmol/g gave maximal sensitivity and specificity with an area un-
der the ROC curve of 0.838 (95% CI 0.749 to 0.927) (Sezer 2014). We
constructed a 2 x 2 table based on this cut-oJ and calculated diag-
nostic test accuracy statistics (Table 4).
In the Yang study, 691 children and adults with chronic liver disease
including 178 with WD (treatment-naive) as assessed by Leipzig cri-
teria underwent liver biopsy pre-treatment with copper measure-
ment by atomic absorption spectroscopy (Yang 2015). In the WD
group 104 were male, 74 female and mean age was 19.7 years. The
authors gave diagnostic accuracy figures at cut-oJs in a group in
which cholestatic diseases such as primary biliary cirrhosis, pri-
mary sclerosing cholangitis were excluded with total of 465 in the
chronic liver disease group. The traditional Leipzig criteria cut-oJ
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of 4 μmol/g gave a sensitivity of 94.4% (95% CI 89.9% to 97.3%) and
a specificity of 96.8% (95% CI 94.75% to 98.2%) (Table 4). ROC curve
analysis undertaken by the authors generated a cut-oJ of 3.3 μmol/
g with an area under the ROC curve of 0.987 (Yang 2015). We con-
structed a 2 x 2 table based on this cut-oJ and calculated diagnos-
tic test accuracy statistics (Table 4).
Index test - 24-hour urinary copper
Three studies evaluated various thresholds of 24-hour urinary cop-
per (268 participants, of whom 101 had WD) (Lu 2010; Nicastro 2010;
Sezer 2014). Two studies were conducted in Europe (one in Italy
(Nicastro 2010) and one in Turkey (Sezer 2014)) and one study was
conducted in China (Lu 2010). All three studies were conducted in
children (Lu 2010; Nicastro 2010; Sezer 2014).
In the Leipzig criteria a score for 24-hour urinary copper is as-
signed based on number times ULN (Table 1) with greater than 1.6
μmol/24 hours and 0.64 μmol/24 hours indicative of WD in adults
and children respectively. Although all three studies are undertak-
en in children, only the Nicastro study gives diagnostic accuracy fig-
ures approximating the paediatric cut-oJ used in the Leipzig crite-
ria (Nicastro 2010), with the remaining two studies giving diagnos-
tic accuracy figures for the adult cut-oJ used in the Leipzig criteria
(Table 1) (Lu 2010; Sezer 2014 ).
The cut-oJs defined by the Leipzig criteria (0.64 μmol/24 hours
and 1.6 μmol/24 hours) was reported by all three studies (Lu 2010;
Nicastro 2010; Sezer 2014) and two of the three studies reported
other thresholds of 0.8 μmol/24 hours and 1.06 μmol/24 hours, de-
termined as the 'optimal' or 'best fitting' threshold by ROC curve
analysis (Lu 2010; Sezer 2014). Sensitivity and specificity results for
all thresholds are presented in a figure (Figure 5); 2 x 2 tables, sen-
sitivity, specificity, PPV, NPV, LR+ and LR- for all thresholds are pre-
sented in an additional table (Table 5) and the results for the cut-
oJs defined by the Leipzig criteria are presented in a summary of
findings table (Summary of findings 3).
 
Figure 5.   Forest plot of tests: 11 24-hour urinary copper (Leipzig criteria threshold 0.64 μmol/24 hours), 12 24-hour
urinary copper (Leipzig criteria threshold 1.6 μmol/24 hours), 13 24-hour urinary copper (threshold 0.8 μmol/24
hours), 14 24-hour urinary copper (threshold 1.06 μmol/24 hours).
 
The Lu study was conducted in 26 children with WD and 68 with
non-WD-related chronic liver disease (Lu 2010). 24-hour urinary
copper was the analyte of interest and was measured using ICP
mass spectrometry. The traditional Leipzig criteria cut-oJ of 1.6
μmol/24 hours gave a sensitivity of 50% (95% CI 29.9% to 70.1%)
and a specificity of 97.1% (95% CI 89.8% to 99.6%) (Table 5). The
study determined that the optimum cut-oJ for 24-hour urinary cop-
per was 0.8 μmol/24 hours, with an area under the curve of 0.909
(95% CI 0.839 to 0.979) (Lu 2010). We constructed a 2 x 2 table based
on this cut-oJ and calculated diagnostic test accuracy statistics
(Table 5).
As stated above, in the Nicastro study, 40 children with treat-
ment-naive WD (elevated transaminases or family screening) and
58 age- and gender-matched controls with non-WD-related chron-
ic liver disease were evaluated (Nicastro 2010). In the WD group
there were 26 males and 14 females, age range 1.1 years to 20.9
years, with a median of 6.1 years. Urine copper was measured by
atomic absorption spectroscopy. ROC curve analysis conducted
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by the study authors showed that a cut-oJ of 0.64 μmol/24 hours
gave maximal sensitivity and specificity with an area under the ROC
curve of 0.91 (95% CI 0.85 to 0.97) (Nicastro 2010). We constructed a
2 x 2 table based on this cut-oJ and calculated diagnostic test accu-
racy statistics: sensitivity 78.9% (95% CI 62.7% to 90.5%) and speci-
ficity 87.9% (95% CI 76.7% to 95.0%) (Table 5). Nicastro also pre-
sented the other traditional Leipzig criteria cut-oJ of 1.6 μmol/24
hours gave a sensitivity of 65.8% (95% CI 48.7% to 80.4%) and a
specificity of 96.3% (95% CI 90.8% to 100%) (Table 5).
As stated above, the Sezer study was conducted in 35 children
with WD (treatment-naive) as defined by the Leipzig criteria (Table
1) and 41 age- and gender-matched controls with non-WD-related
chronic liver disease (Sezer 2014). In the WD group mean age was
10.2 years with a range of 8 years to 16.5 years and 57.1% (20) male,
42.9% (15) female. 24-hour urine copper was measured by atom-
ic absorption spectroscopy. The traditional Leipzig criteria cut-oJ
of 1.6 μmol/24 hours gave a sensitivity of 80.0% (95% CI 63.1% to
91.6%) and a specificity of 75.6% (95% CI 59.7% to 87.6%) (Table
5). ROC curve analysis was conducted by the authors and showed
that a cut-oJ of 1.06 μmol/24 hours gave maximal sensitivity and
specificity with an area under the ROC curve of 0.843 (95% CI 0.752
to 0.934) (Sezer 2014). We constructed a 2 x 2 table based on this
cut-oJ and calculated diagnostic test accuracy statistics (Table 5).
D I S C U S S I O N
The diagnosis of WD is a heterogenous process involving a combi-
nation of clinical, biochemical, immunological and genetic test re-
sults (Table 1). The limited evidence provided by the studies in this
review suggests that at the optimum cut-oJs quoted above based
on ROC curve analysis, vary in terms of the method used for each
analyte and the age of participant groups. The EASL guidelines on
WD provided a narrative, expert-based review on the evidence sup-
porting the original Leipzig criteria (EASL 2012).
Three main studies are provided to support caeruloplasmin cut-
oJs used (Merle 2009; Perlman 1979; Steindl 1997). In the Perlman
study, laboratory measures of copper metabolism were assessed
for 25 people with WD (diagnosis based on KF ring presence in ab-
sence of cholestasis) and 20 people with chronic active hepatitis
(Perlman 1979). Caeruloplasmin was measured by both oxidase
and an immunological method, however, only one reference range
is quoted without a reference (0.22 g/L to 0.49 g/L) and although
the authors describe the participants as children, ages ranged from
4 years to 20 years. The cut-oJ evaluated was < 22 mg/dL which
the authors concluded could not accurately differentiate WD from
chronic active hepatitis as 28% with WD were above this and 25%
with chronic active hepatitis were below this cut-oJ. In the Steindl
study, caeruloplasmin was measured by radial immunodiffusion in
a mixed hepatic and neurological group of 55 children and adults
with WD (Steindl 1997). Diagnosis was based on Sternlieb's criteria
and those with KF rings, neurological features had a significantly
lower caeruloplasmin compared with those without any of these
features (Sternlieb 1990). No controls were used and although the
method was referenced and a range quoted (0.20 to 0.60 g/L), how
this was derived was unclear. Heterozygotes have been shown to
have low caeruloplasmin (< 0.2 g/L) in 20% of cases but having a
normal allele will have none of the clinical phenotype (Gromadzka
2010). Caeruloplasmin is an acute-phase protein and so may be el-
evated in inflammation as well as in those with increased endoge-
nous oestrogen (pregnancy) or exogenous oestrogen (oral contra-
ceptive pill).
For discussion of cut-oJ values for 24-hour urinary copper that sup-
port the Leipzig criteria, the EASL guidelines (EASL 2012) makes
reference to a number of WD case-series that do not have control
data and have limited detail regarding laboratory method use to
measure the analyte or how the reference range used was derived
(Ferenci 2007; Giacchino 1997; Sanchez-Albisua 1999; Steindl 1997).
The EASL guidelines, however, do highlight some important points,
that the cut-oJ for adults is higher than in children and that lev-
els may be lower in asymptomatic siblings and that false positives
for 24-hour urinary copper can occur in the presence of non-WD
cholestatic liver disease and nephrotic syndrome (EASL 2012).
Previous commentary has suggested that measurement of hepatic
copper content is the gold standard for diagnosing WD (EASL 2012);
however, even the authors of one of the largest studies to date on
this subject highlights studies of where hepatic copper may give
false negative results, due to sampling error or possible differences
in hepatic copper distribution (Ferenci 2005).
Summary of main results
We have tabulated a summary of the main results from this review
that quote diagnostic accuracy figures for relevant Leipzig criteria
(Table 1) for each index test in summary of findings tables and for-
est plots (Summary of findings 1, Summary of findings 2, Summary
of findings 3, Figure 3, Figure 4, Figure 5).
In the five studies eligible for this review that provided a prima-
ry outcome for reporting for caeruloplasmin, the optimum cut-oJ
varies between 0.14 g/L to 0.2 g/L (Mak 2008; Merle 2009; Nicastro
2010; Sezer 2014; Xu 2018). In general, these studies were well-de-
signed, providing a clear WD disease definition, details of the lab-
oratory method used, use of appropriate controls and evaluation
of cut-oJs using ROC curve analysis. The differences in the sug-
gested optimum cut-oJs may reflect the different methods used
for caeruloplasmin evaluation, clinical presentation, possible age
of the participants involved and their ethnicity. Some of these stud-
ies evaluated caeruloplasmin in those with mild hepatic WD (Nicas-
tro 2010, Sezer 2014), whilst others were undertaken in those with
hepatic of variable severity and neurological WD (Mak 2008; Merle
2009; Xu 2018). Caeruloplasmin levels are lower in neonates rising
to adult range in two to three years, however, it rises during preg-
nancy, in women on the oral contraceptive pill and in those expe-
riencing acute inflammation. Two of the studies were undertaken
in children (Nicastro 2010, Sezer 2014), two in a mixed children and
adult population (Mak 2008, Xu 2018) and one in an adult-only pop-
ulation (Merle 2009) (Table 2).
As it is synthesised in the liver, caeruloplasmin is lower in other
causes of chronic liver disease apart from WD, but it is also low-
ering in protein-losing states such as enteropathies and nephrot-
ic syndrome (Cox 1966; EASL 2012). Previous work has suggested
that those on chelation therapy have lower caeruloplasmin levels
(Grazyna 2014); however, this does not appear to be the case in
the Merle study, where 65% where on penicillamine therapy but
differences in assay methodology may also have contributed to
this effect (Merle 2009). Different methods for a particular analyte,
take caeruloplasmin in this instance, may vary in terms of reference
range, bias and precision. Therefore, where cut-oJ values are used
the importance of considering method is paramount as the same
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sample run for the same analyte with a different method is likely to
generate a different result for the reasons given above.
For 24-hour urinary copper there is limited evidence presented for
the adult cut-oJ of > 1.6 μmol/24 hours (EASL 2012); however, our
review included three studies evaluating 24-hour urinary copper
cut-oJs in children with WD-related chronic liver disease (Lu 2010;
Nicastro 2010; Sezer 2014) (Table 2). The Lu study used inductively
coupled mass spectrometry evaluating a Chinese population and
Sezer, Nicastro used atomic absorption spectroscopy in a Turkish
and Italian population, respectively (Lu 2010; Nicastro 2010; Sezer
2014). Both studies were well-designed, with clear criteria for WD
diagnosis (Table 1), appropriate age, gender matched controls. The
difference in terms of the optimum cut-oJs may be due to different
methods and ethnicity (Table 2).
For cut-oJs for hepatic copper, four studies were eligible for this
review, with different age groups, ethnicity and method used for
index test analysis (Table 2). The Ferenci study was well designed,
with clearly defined WD criteria carried out on a mixed children and
adult population. Appropriate laboratory methods evaluating he-
patic copper using atomic absorption spectroscopy were utilised
(Ferenci 2005). The optimum cut-oJ based on ROC curve analy-
sis was 1.2 μmol/g giving a sensitivity of 96.4% with a specificity
of 95.4% (Ferenci 2005). This contrasts with the higher cut-oJ of
4 μmol/g used in the Leipzig criteria, however, as Ferenci discuss-
es, this original cut-oJ was based on a sample of only seven peo-
ple with WD (Ferenci 2005). Interestingly, the Chinese-based Yang
study, also in children and adults, offered a robust defence of the 4
μmol/g cut-oJ for hepatic copper and showed that in their popula-
tion this resulted in a sensitivity of 99.4% and a specificity of 96.1%
(Yang 2015). This has a larger participant sample than the former
European-based study, had a clearly defined WD disease criteria,
clear methodology in an adult population. Again, such differences
may be due to the differences in the method but may reflect eth-
nicity and different distribution in disease causing alleles in each
population.
Both Nicastro and Sezer evaluated hepatic copper using two dif-
ferent methods of flame atomic absorption spectroscopy in chil-
dren with hepatic disease in Italy and Turkey, respectively (Nicastro
2010; Sezer 2014). Nicastro did not undertake ROC analysis how-
ever at the cut-oJ of 4μmol/g used in the Leipzig criteria (Table 1)
had a sensitivity of 87.5% and specificity of 96.6% (Nicastro 2010).
Sezer found that the cut-oJ of 4μmol/g had a sensitivity of 65%,
specificity of 77% and that decreasing the threshold to 1.5μmol/g
increased sensitivity to 91.4% but with specificity of 65.8% (Sezer
2014). The differences between the two studies may be due to dif-
ferences in: disease severity, genotypes between the two popula-
tions, and method of measuring hepatic copper.
Strengths and weaknesses of the review
The strength of this review is the adoption of high methodological
standards, in particular, screening of 10,638 studies and detailed
scrutiny of 20 studies allowed us to identify important implications
for future research about the diagnostic accuracy of biochemical
testing for WD in both children and adults. These implications re-
late to both the methodological conduct of future diagnostic stud-
ies but also the optimum method for monitoring chelation therapy
for WD.
Weaknesses of the review include the small number of includ-
ed eligible studies, data from which were unsuitable for pooling
in a meta-analysis, due to differences in methods used for index
tests. Key differences between studies include differences in assay
methodology, different cut-oJ values for diagnostic thresholds, dif-
ferent age and ethnicity groups. Key biases of note were in partic-
ipant selection and reference standard that may limit external va-
lidity of the study findings.
Applicability of findings to the review question
The findings of this review are applicable to the review question, al-
though all included studies used the Leipzig criteria for WD disease
definition, some of the included studies had limited detail on other
methodologies used to calculate the score apart from the relevant
index test being evaluated. A high proportion of the studies identi-
fied by our search were excluded from the review because of lack
of disease definition and poorly defined index test methodology
or reference range source. These methodological weakness could
have resulted in bias or over estimation of the accuracy of the index
test.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Any disease cut-oJ for biochemical testing for Wilson's disease
(WD) is method dependent and the specificity of the results should
be interpreted with caution in the presence of other causes of
chronic liver disease. Clinicians should be aware that there is no
gold standard test for diagnosing WD and that a combination of
clinical and laboratory testing may be required for diagnosis.
Implications for research
Well-designed studies are needed to evaluate whether cut-oJs for
biochemical testing for WD are affected by age, clinical presenta-
tion and ethnicity. The invasiveness of liver biopsy has led to a de-
cline in its routine use; however, use of non-invasive serum fibrosis
markers may offer an opportunity to evaluate target organ damage
particularly given the protean manifestation of hepatic disease in
WD. Further diagnostic marker testing with standardised method-
ologies, with appropriately validated cut-oJs and disease severity
score, is only likely to succeed in a large multinational WD registry
setting if this is to have impact on clinical practice. Such a facili-
ty would also allow for evaluation of biochemical tests to monitor
chelation therapy.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Patient sampling Case-control study
Patient characteristics and setting People with WD (hepatic, neuropsychiatric or
asymptomatic), normal controls and those
with alternative confirmed hepatic pathology
Index tests Hepatic copper measured using atomic ab-
sorption spectroscopy
Target condition and reference standard(s) WD and the Leipzig criteria
Flow and timing Participant flow not clearly delineated
Comparative  
Notes Given case-control design, selection bias is




Risk of bias Applicabili-
ty concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? No    
Ferenci 2005 
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Was a case-control design avoided? No    
Did the study avoid inappropriate exclusions? Yes    
    High Low
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of the results of the refer-
ence standard?
No    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the results of
the index tests?
No    
Does prior knowledge of a single index test result affect reference standard con-
duct?
No    
    High Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference standard? No    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient sampling Case-control study
Patient characteristics and setting Hepatic disease unknown
Index tests 24-hour urinary copper measured by ICP
mass spectrometry
Target condition and reference standard(s) WD and Leipzig criteria
Flow and timing Flow of participants not clearly delineated
Comparative  
Lu 2010 
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Notes Given the case-control design, selection bias




Risk of bias Applicabili-
ty concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? No    
Was a case-control design avoided? No    
Did the study avoid inappropriate exclusions? Yes    
    High Low
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of the results of the refer-
ence standard?
No    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the results of
the index tests?
No    
Does prior knowledge of a single index test result affect reference standard con-
duct?
No    
    High Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference standard? No    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient sampling Case-control study
Mak 2008 
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Patient characteristics and setting Those with WD (hepatic, neuropsychiatric or
asymptomatic), normal controls, undiagnosed
hepatic or neurological deficit
Index tests Caeruloplasmin using nephelometry Beckman
Coulter IMMAGE
Target condition and reference standard(s) WD and the Leipzig criteria
Flow and timing Participants tested at presentation prior to
commencement of chelation therapy
Comparative  
Notes Due to the nature of the clinical reference stan-




Risk of bias Applicabili-
ty concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? No    
Was a case-control design avoided? No    
Did the study avoid inappropriate exclusions? Yes    
    High Low
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of the results of the ref-
erence standard?
No    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the results
of the index tests?
No    
Does prior knowledge of a single index test result affect reference standard con-
duct?
No    
    High Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference standard? No    
Mak 2008  (Continued)
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Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient sampling Case-control study
Patient characteristics and setting People with WD (hepatic or neurological),
normal controls and those with alternative
confirmed hepatic pathology
Index tests Caeruloplasmin nephelometry Dade Behring
Target condition and reference standard(s) WD and the Leipzig criteria
Flow and timing Flow of participants not clearly delineated
Comparative  
Notes Given the case-control design, selection is




Risk of bias Applicabili-
ty concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? No    
Did the study avoid inappropriate exclusions? Yes    
    High Low
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of the results of the refer-
ence standard?
No    
If a threshold was used, was it pre-specified? No    
    High Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Merle 2009 
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Were the reference standard results interpreted without knowledge of the results of
the index tests?
No    
Does prior knowledge of a single index test result affect reference standard con-
duct?
No    
    High Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference standard? No    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient sampling Case-control study
Patient characteristics and setting People with WD (hepatic or asymptomatic family
screening), normal controls and those with alterna-
tive confirmed hepatic pathology
Index tests Caeruloplasmin by radial immunodiffusion NOR-
Partigen Behring
Urine copper by flame absorption spectrophotom-
etry
Hepatic copper by flame absorption spectropho-
tometry
Target condition and reference standard(s) WD and the Leipzig criteria
Flow and timing Flow of participants and timing of tests clearly de-
lineated
Comparative  
Notes Given the case-control study design, selection bias




Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? No    
Nicastro 2010 
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Was a case-control design avoided? No    
Did the study avoid inappropriate exclusions? Yes    
    High Low
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of the results of the
reference standard?
No    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the re-
sults of the index tests?
No    
Does prior knowledge of a single index test result affect reference standard
conduct?
No    
    High Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference standard? No    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient sampling Case-control study
Patient characteristics and setting People with WD (hepatic), normal controls and
those with alternative confirmed hepatic patholo-
gy
Index tests Hepatic copper by atomic absorption spectropho-
tometry AA-6701F Shimadzu; urine copper by
atomic absorption spectrophotometry AA-6701F
Shimadzu; caeruloplasmin by immunoturbidimetry
Roche Modular
Target condition and reference standard(s) WD and the Leipzig criteria
Sezer 2014 
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Flow and timing Flow of participants and timing clearly delineated
Comparative  
Notes Given the case-control study design, selection bias




Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? No    
Was a case-control design avoided? No    
Did the study avoid inappropriate exclusions? Yes    
    High Low
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of the results of the
reference standard?
No    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the re-
sults of the index tests?
No    
Does prior knowledge of a single index test result affect reference standard
conduct?
No    
    High Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference standard? No    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
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Study characteristics
Patient sampling Cross-sectional study
Patient characteristics and setting All participants that had ceruloplasmin
analysed were eligible. Testing and records
were accessed in a university hospital centre
Index tests Ceruloplasmin by nephelometry, Beckman
Coulter Immage
Target condition and reference standard(s) WD and the Leipzig criteria
Flow and timing Flow of participants clearly delineated
Comparative  
Notes Due to the cross-sectional study design, selec-




Risk of bias Applicabili-
ty concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? No    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    High Low
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of the results of the ref-
erence standard?
No    
If a threshold was used, was it pre-specified? Yes    
    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the results
of the index tests?
No    
Does prior knowledge of a single index test result affect reference standard con-
duct?
No    
    High Low
Xu 2018 
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DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference standard? Unclear    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient sampling Prospective cohort
Patient characteristics and setting People with suspected WD (hepatic), relatives of
people with WD and those with alternative con-
firmed hepatic pathology
Index tests Hepatic copper by atomic absorption spectropho-
tometry Bejing Purkinje General Instruments
Target condition and reference standard(s) WD and the Leipzig criteria
Flow and timing Flow of participants clearly delineated
Comparative  
Notes Design and conduct of study minimised risk of
bias leading to inaccurate conclusion with popu-




Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? No    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
    High Low
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of the results of the
reference standard?
No    
If a threshold was used, was it pre-specified? Yes    
Yang 2015 
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    Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the re-
sults of the index tests?
No    
Does prior knowledge of a single index test result affect reference standard con-
duct?
No    
    High Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference standard? No    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
    Low  
Yang 2015  (Continued)
ICP: inductively coupled plasma; WD: Wilson's disease
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Causa 1997 Did not use Leipzig criteria for diagnosis of WD
Frommer 1981 Did not use Leipzig criteria for diagnosis of WD
Gibbs 1979 Did not use Leipzig criteria for diagnosis of WD
Gnanou 2006 Method comparison study undiagnosed cohort
Lech 2007 Did not use Leipzig criteria for diagnosis of WD
Li 1983 Did not use Leipzig criteria for diagnosis of WD
Liggi 2013 Case-series of people with WD, no controls
Mahjoub 2012 Lack of WD definition and clarity of methods used
Markowitz 1955 Lack of WD definition and clarity of methods used
Mzhel'skaia 1994 Did not use Leipzig criteria for diagnosis of WD
Prasad 1998 Caeruloplasmin oxidase method used which is not used for Leipzig criteria. Also unclear if children
are or were on any chelation therapy
Siotto 2014 Caeruloplasmin oxidase method used which is not used for Leipzig criteria
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WD: Wilson's disease
 
Characteristics of studies awaiting classification [ordered by study ID]
 
Study characteristics
Patient sampling Case-control, convenience
Patient characteristics and setting 66 children with confirmed WD and 88 children without WD
Index tests 24-hour urinary copper levels
Target condition and reference standard(s) WD and unclear reference standard, abstract only
Flow and timing Flow of participants not clearly delineated, abstract only






Patient sampling Case-control, convenience
Patient characteristics and setting 40 people with WD, 40 carriers and 20 normal controls
Index tests Caeruloplasmin and 24-hour urinary copper
Target condition and reference standard(s) WD, unclear reference standard, abstract only
Flow and timing Flow of participants not clearly delineated, abstract only
Comparative Unclear, abstract only
Notes  
Zhou 2019 
Abbreviations: WD: Wilson's disease
 
 
D A T A
Presented below are all the data for all of the tests entered into the
review.
 
Table Tests.   Data tables by test
Test No. of studies No. of partici-
pants
1 Caeruloplasmin (Leipzig criteria threshold 0.1 g/L) 2 291
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Test No. of studies No. of partici-
pants
2 Caeruloplasmin (Leipzig criteria threshold 0.2 g/L) 4 4415
3 Caeruloplasmin (other threshold 0.14 g/L) 2 291
4 Caeruloplasmin (other threshold 0.15 g/L) 1 4048
5 Caeruloplasmin (other threshold 0.18 g/L) 1 98
6 Caeruloplasmin (other threshold 0.19 g/L) 1 161
7 Hepatic copper (Leipzig criteria threshold > 4 μmol/g) 4 1128
8 Hepatic copper (other threshold 1.2 μmol/g) 1 333
9 Hepatic copper (other threshold 1.5 μmol/g) 1 76
10 Hepatic copper (other threshold 3.3 μmol/g) 1 643
11 24-hour urinary copper (Leipzig criteria threshold 0.64 μmol/24 hours) 1 96
12 24-hour urinary copper (Leipzig criteria threshold 1.6 μmol/24 hours) 3 266
13 24-hour urinary copper (threshold 0.8 μmol/24 hours) 1 94
14 24-hour urinary copper (threshold 1.06 μmol/24 hours) 1 76
 
 
Test 1.   Caeruloplasmin (Leipzig criteria threshold 0.1 g/L).
 
 
Test 2.   Caeruloplasmin (Leipzig criteria threshold 0.2 g/L).
 
 
Test 3.   Caeruloplasmin (other threshold 0.14 g/L).
 
 
Test 4.   Caeruloplasmin (other threshold 0.15 g/L).
 
 
Test 5.   Caeruloplasmin (other threshold 0.18 g/L).
 
 
Test 6.   Caeruloplasmin (other threshold 0.19 g/L).
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Test 7.   Hepatic copper (Leipzig criteria threshold > 4 μmol/g).
 
 
Test 8.   Hepatic copper (other threshold 1.2 μmol/g).
 
 
Test 9.   Hepatic copper (other threshold 1.5 μmol/g).
 
 
Test 10.   Hepatic copper (other threshold 3.3 μmol/g).
 
 
Test 11.   24-hour urinary copper (Leipzig criteria threshold 0.64 μmol/24 hours).
 
 
Test 12.   24-hour urinary copper (Leipzig criteria threshold 1.6 μmol/24 hours).
 
 
Test 13.   24-hour urinary copper (threshold 0.8 μmol/24 hours).
 
 
Test 14.   24-hour urinary copper (threshold 1.06 μmol/24 hours).
 
 











Table 1.   Leipzig criteria 
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> 0.2 g/L 0
0.1 - 0.2 g/L 1





> 4 μmol/g 2
0.8 - 4.0 µmol/g 1




1 - 2 x upper limit normal 1
> 2 x upper limit normal 2
Normal but > 5 x upper limit normal after D-penicillamine 2
Mutational analysis
2 chromosomes affected 4
1 chromosome affected 1
No mutation detected 0
Table 1.   Leipzig criteria  (Continued)























Participants included in DTA analyses of
this review
• 114 children and adults with WD
Table 2.   Characteristics of included studies 
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• 219 chronic liver disease controls
Participants not included in DTA analy-
ses of this review
• 26 normal controls (included for ref-
erence interval of hepatic copper
content)












Hepatic Participants included in DTA analyses of
this review
• 26 children with WD


















Participants included in DTA analyses of
this review
• 59 children and adults with WD
• 71 family members (49 heterozy-
gotes, 22 wild type homozygotes),
• Validation group of 25 with suspect-
ed WD
• 40 normal controls with serum ceru-
loplasmin concentrations ≤ 0.20 g/L
Participants not included in DTA analy-
ses of this review
• 650 normal controls with serum
ceruloplasmin concentrations > 0.20




















Participants included in DTA analyses of
this review
• 110 adults with WD
• 51 with cirrhosis not due to WD
Participants not included in DTA analy-
ses of this review
• 52 healthy controls (DTA analyses of
serum ceruloplasmin oxidase activ-
ity of WD participants and healthy
controls were conducted in the orig-









Leipzig criteria: 0.2 g/L
and 0.1 g/L
Other (from Mak 2008):











Participants included in DTA analyses of
this review
• 40 children with WD
• 58 age, sex-matched with non-WD-
related chronic liver disease
Table 2.   Characteristics of included studies  (Continued)
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Hepatic Participants included in DTA analyses of
this review
• 35 children with WD
• 41 with non-WD-related chronic liver
disease


















Participants included in DTA analyses of
this review
• 178 children and adults with WD
• 465 with non-WD-related chronic liv-


















Participants included in DTA analyses of
this review
• 297 children and adults with WD
• 3751 with non-WD-related chron-
ic liver disease and nephrotic syn-
drome
Table 2.   Characteristics of included studies  (Continued)
Abbreviations: CI: Confidence interval; DTA: diagnostic test accuracy; USA: United States of America; WD: Wilson's disease
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Threshold(s) according to the Leipzig criteria







































































































































































































































































































































Table 3.   Diagnostic test accuracy of index tests - caeruloplasmin  (Continued)
Abbreviations: CI: confidence interval; PPV: positive predictive value; NPV: negative predictive value; LR+: positive-likelihood ratio; LR-: negative-likelihood ratio; NA: not available;
NE: not estimable.
a. Due to rounding to the appropriate number of decimal places, CIs presented may not be symmetric around the point estimate
b. Not estimable: No false positives (FP = 0) results in a LR+ of infinity and CIs of 100% to 100% for PPV
c. 'Other' threshold reported in the studies were defined as the 'most useful cut-oJ value' (Mak 2008, Xu 2018), 'the greatest sum of sensitivity and specificity of immunoreactive
ceruloplasmin concentrations' (Merle 2009) and the other thresholds examined in Nicastro 2010 were informed by Mak 2008
 
 













































































































































Threshold according to the Leipzig criteria






































































































































































































































































Abbreviations: CI: confidence interval; PPV: positive-predictive value; NPV: negative-predictive value; LR+: positive-likelihood ratio; LR-:negative-likelihood ratio; NA: not avail-
able; NE: not estimable; WD: Wilson's disease
a. Due to rounding to the appropriate number of decimal places, CIs presented may not be symmetric around the point estimate
b. 'Other' threshold reported in the studies were defined as the 'most useful cut-oJ value' (Ferenci 2005; Yang 2015) or the 'optimum' cut-oJ value (Sezer 2014)
 
 















Threshold (s) according to the Leipzig criteria















































































































Positive 31 12Study ID: Sezer 2014
Negative 4 29
88.6% 70.7% 72.1% 87.9% 3.03 0.16












































































































































Table 5.   Diagnostic test accuracy of index tests - 24-hour urinary copper  (Continued)
Abbreviations: CI: confidence interval; PPV: positive-predictive value; NPV: negative-predictive value; LR+: positive-likelihood ratio; LR-: negative-likelihood ratio; hrs: hours; NA:
not available; NE: not estimable
a. Due to rounding to the appropriate number of decimal places, CIs presented may not be symmetric around the point estimate
b. In Lu 2010, 0.8 μmol/24 hours is the 'best fitting' cut-oJ value (compared to the Leipzig defined cut-oJ for adults 1.6 μmol/24 hours) and in Sezer 2014, the thresholds were
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A P P E N D I C E S
Appendix 1. Electronic search strategy
 
Database/ Resource Strategy
Cochrane Central Register of
Controlled Trials (CENTRAL)
and Cochrane Database of Sys-
tematic Reviews (CDSR)
[Advanced Search – Search Builder]
#1 MeSH descriptor: [Hepatolenticular Degeneration] this term only
#2 (hepatolenticular degeneration) or (hepatic lenticular degeneration)
#3 "*wilson* disease"
#4 #1 or #2 or #3
#5 MeSH descriptor: [Ceruloplasmin] explode all trees
#6 caeruloplasmin or ceruloplasmin or apocaeruloplasmin or apoceruloplasmin or holocaerulo-
plasmin or holoceruloplasmin or holo-caeruloplasmin or holo-ceruloplasmin
#7 "urinary copper" or "urine copper" or "hepatic copper" or "liver copper"
#8 #5 or #6 or #7
#9 #4 and #8
PubMed (1946 onwards) ("Hepatolenticular Degeneration"[Mesh] OR hepatolenticular degeneration OR hepatic lenticular
degeneration OR “wilson disease” OR “wilsons disease” OR “wilson’s disease”) AND (caeruloplas-
min OR apocaeruloplasmin OR apoceruloplasmin OR holocaeruloplasmin OR holoceruloplasmin
OR holo-caeruloplasmin OR holo-ceruloplasmin OR “urinary copper” OR “urine copper” OR “hepat-
ic copper” OR “liver copper”)
CINAHL EBSCO (1982 onwards) ( (MH "Hepatolenticular Degeneration") OR TX ( hepatolenticular degeneration OR hepatic lentic-
ular degeneration OR “wilson disease” OR “wilsons disease” OR “wilson’s disease” ) ) AND TX
( ( caeruloplasmin OR ceruloplasmin OR apocaeruloplasmin OR apoceruloplasmin OR holocaeru-
loplasmin OR holoceruloplasmin OR holo-caeruloplasmin OR holo-ceruloplasmin OR “urinary cop-
per” OR “urine copper” OR “hepatic copper” OR “liver copper” ) )
Embase Ovid (1982 onwards) 1 WILSON DISEASE/
2 ((hepatolenticular AND degeneration) OR "hepatic lenticular degeneration" OR "wilson disease"
OR "wilsons disease" OR "wilson’s disease").ti,ab
3 1 OR 2
4 CERULOPLASMIN/
5 (caeruloplasmin OR ceruloplasmin OR apocaeruloplasmin OR apoceruloplasmin OR holocaerulo-
plasmin OR holoceruloplasmin OR holo-caeruloplasmin OR holo-ceruloplasmin).ti,ab
6 ("urinary copper" OR "urine copper" OR "hepatic copper" OR "liver copper").ti,ab
7 4 OR 5 OR 6
8 3 AND 7
Web of Science’s Conference
Proceedings Citation Index
(CPCI) (1990 onwards)
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(caeruloplasmin OR ceruloplasmin OR apocaeruloplasmin OR apoceruloplasmin OR holocaerulo-
plasmin OR holoceruloplasmin OR holo-caeruloplasmin OR holo-ceruloplasmin OR “urinary cop-
per” OR “urine copper” OR “hepatic copper” OR “liver copper”) [TOPIC]
British Library’s ZETOC (1993
onwards) for conference ab-
stracts
[Conference Search]
Search 1: “Wilson* disease” [all fields]
Search 2: “hepatolenticular degeneration” [all fields]
PROSPERO #1 MeSH DESCRIPTOR Hepatolenticular Degeneration EXPLODE ALL TREES
#2 "Hepatolenticular Degeneration"
#3 "hepatic lenticular degeneration"
#4 "wilson* disease"
#5 #1 OR #2 OR #3 OR #4
Clinicaltrials.gov Condition/ Disease: Wilson disease
Other terms: caeruloplasmin OR ceruloplasmin OR apocaeruloplasmin OR apoceruloplasmin OR
holocaeruloplasmin OR holoceruloplasmin OR holo-caeruloplasmin OR holo-ceruloplasmin OR
“urinary copper” OR “urine copper” OR “hepatic copper” OR “liver copper”
WHO ICTRP Wilson disease
  (Continued)
 
Appendix 2. QUADAS-2 methodological assessment tool
QUADAS-2 is structured so that four key domains are each rated in terms of the risk of bias and the concern regarding applicability to the
research question (as defined above). Each key domain has a set of signalling questions to help reach the judgments regarding bias and
applicability.
Domain 1: Participant selection
Risk of bias - could the selection of participants have introduced bias?
1. Was a consecutive or random sample of patients enrolled?
 
Assessment Description
Yes if the articles clearly states that a consecutive or random samples have been enrolled
No if it is clear that this was not the case (e.g. if a study included participants 'at the discretion of the
clinician')
Unclear in other cases where it is not clear if consecutive or random samples have been enrolled
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Yes if the enrolled sample was a random or consecutive enrolment of participants with suspected WD
and not separate samples from WD-positive participants and healthy controls
No if the enrolled samples consist of WD-confirmed cases and healthy controls
Unclear if the sampling regarding case-control design was not clear
  (Continued)
 
3. Did the study avoid inappropriate exclusions?
Inappropriate exclusions include participants with tremor and chronic liver disease of unknown cause etc.
 
Assessment Description
Yes if inappropriate exclusions were not found in the included study
No if reasons for inappropriate exclusion were found




4. Could the selection of patients have introduced bias?
 
Assessment Description
Low risk if all questions were scored 'Yes', or a maximum of one question with unclear
High risk If at least one question was scored as 'No'
Unclear risk If at least two questions were scored as unclear and one as 'No'
 
 
5. Concerns regarding applicability
Is there concern that the included participants do not match the review question?
 
Assessment Description
Low concern if all included participants according to our definition and if they were suspected of WD
High concern If at least 10% of the included participants were suspected of WD
Unclear concern if it is unclear whether the study fulfilled either the criteria for low concern or for high concern
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Domain 2: Index test(s)
Describe the index test and how it was conducted and interpreted - this will vary with each test method. If more than one index test was
used, please complete for each test.
Risk of bias - could the conduct or interpretation of the test have introduced bias?
1. Were the index test results interpreted without knowledge of the results of the reference standard?
 
Assessment Description
Yes if the index test is conducted and interpreted without the knowledge of the results of the reference
standard
No if the index test is interpreted with the knowledge of the results of the reference standard




2. If a threshold was used, was it pre-specified?
 
Assessment Description
Yes thresholds were used and were clearly defined
No thresholds were not used or were not clearly defined
Unclear unclear whether thresholds were used or predefined
 
 
3 Could the conduct or interpretation of the index test have introduced bias?
 
Assessment Description
Low risk if 'yes' classification for both questions above
High risk if 'no' classification for any of the above two questions
Unclear risk if 'unclear' classification for any of the above two questions, but without a 'no' classification for any
of the above two questions
 
 
4. Concerns regarding applicability
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Low concern if the index test used for the diagnosis of Wilsons was a molecular assay as defined in our protocol
High concern if the index test used for the diagnosis of Wilsons varies from what was defined in the protocol
Unclear concern if it is unclear whether the study fulfils criteria for low concern or high concern or if the study pro-
vided limited information regarding the conduct and interpretation of the index test
  (Continued)
 
Domain 3: Reference standard
Describe the reference standard and how it was conducted and interpreted.
Risk of bias - could the reference standard, its conduct, or its interpretation have introduced bias?
1. Is the reference standard likely to correctly classify the target condition?
 
Assessment Description
Yes if the reference standard used was consistent with the Leipzig criteria in the diagnosis of WD
No if the test used as reference standard was a test other than those listed in the Leipzig criteria
Unclear if there was no description of the reference standard
 
 
2. Could prior knowledge of a single index test result affect reference standard conduct?
No being a clinical reference standard, for the Leipzig criteria score the index tests are incorporated into the Leipzig score and a single
index test of any of the biochemical tests being evaluated in this review, on it's own will not affect the reference standard conduct.
3. Could the reference standard, its conduct, or its interpretation have introduced bias?
Not applicable as the Leipzig criteria is a clinical reference standard and its application therefore will depend on application of results of
clinical, biochemical and genetic results, including the index tests used within the review.
4. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question?
 
Assessment Description
Low concern if the reference standard was the Leipzig criteria and if the target condition was suspected Wilsons
disease in a patient as defined in our protocol
High concern if the reference standard was a test other than that specified in the Leipzig criteria and if the sub-
jects were not suspected of WD
Unclear concern if it was unclear whether the study fulfilled either the criteria for low concern or for high concern
 
 
Domain 4: Flow and timing
· Describe any participants who did not receive the index test(s) and/or reference standard or who were excluded from the 2 x 2 table (refer
to flow diagram).
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· Describe the time interval and any interventions between index test(s) and reference standard - again, not sure this applies as it is a
clinical reference standard.
Risk of bias - could the participant flow have introduced bias?
1. Was there an appropriate interval between index test(s) and reference standard?
Does not apply - clinical reference standard.
2. Did all participants receive a reference standard?
 
Assessment Description
Yes if all participants underwent testing according to the Leipzig criteria
No if at least one participant did not have the reference standard performed




3. Did participants receive the same reference standard?
 
Assessment Description
Yes if all participants underwent testing according to the Leipzig criteria
No if a different reference standard other than the Leipzig criteria




4. Were all participants included in the analysis?
 
Assessment Description
Yes if all enrolled participants with the target condition that underwent testing using the index test and
reference standard were included in the analysis
No if all enrolled participants were not accounted for in the analysis
Unclear if it is unclear from the study about the inclusion of all enrolled participants in the analysis
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Low concern if the answers to above questions were all YES which means that all participants enrolled in the
study were subjected to the same reference standard and index test, and all participants were in-
cluded in the final analysis
High concern if at least two questions had a 'No' answer
Unclear concern If at least one question had a 'No' answer or it was unclear whether the study fulfilled either the cri-










Positive (+) True positives (TP) False positives (FP)Index test
Negative (-) False negatives (FN) True negatives (TN)
  (Continued)
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